He has extensive experience in creating group therapy interventions for patients with serious illnesses and has successfully integrated ketamine-assisted psychotherapy services within an academic outpatient oncology clinic for cancer patients with depression. He is the principal investigator for a psilocybin-enhanced group psychotherapy intervention for cancer patients with depression and a co-investigator on a study for ketamine-assisted psychotherapy for opioid use disorder. Thielking is board certified in psychiatry, hospice and palliative medicine, and integrative medicine. He is also an adjunct professor at both the University of Utah and Brigham Young University, the company said. To date, Robison has guided thousands of ketamine-assisted therapy sessions and hundreds of Spravato dosing sessions. He was previously a coordinating investigator for a study on MDMA-assisted therapy for eating disorders, sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS).Īs an early adopter and researcher of the use of ketamine in psychiatry, Robison also led a pivotal intravenous ketamine study for treatment-resistant depression by Janssen, leading up to that company's recent FDA-approval of Spravato. Robison is a board-certified psychiatrist and co-founder of Cedar Psychiatry and serves as the medical director for the Center for Change, a leading center for the treatment of eating disorders, Numinus noted. Robison was most recently chief medical officer at Novamind and Thielking, chief scientific officer. In conjunction with the acquisition, Numinus said Dr Reid Robison (MD) and Dr Paul Thielking (MD) have joined the company as chief clinical officer and chief science officer, respectively. "We warmly welcome the Novamind team to Numinus and believe our shared values and focus on client service will ensure a seamless integration as we continue to grow as one unified company," said CEO Nyquvest. The transaction has also provided a strong potential for partnerships in the US and acquisition opportunities, it said, adding that on a proforma basis, the combined business generated C$11.9 million of annual revenues (trailing four quarters reported, as at June 10, 2022). Numinus said the acquisition will grow its client service offerings, geographic reach, and revenues significantly, and provide Numinus and Novamind clients access to a greater variety of services and treatments over the coming months, including the expansion of virtual therapy services at US-based clinics and increased group therapy offerings in Canada.
READ: Numinus Wellness says shareholders have approved resolution in connection with the proposed acquisition of Novamind "This acquisition elevates our collective service offering, and we look forward to helping an even greater number of people access effective and safe treatments to support mental wellness," said Payton Nyquvest, founder and CEO of Numinus, in a statement.
Numinus said the acquisition has positioned the company as a leading integrated mental wellness company providing ketamine- and psychedelic-assisted therapies, with 13 wellness clinics, four clinical research facilities, and a dedicated psychedelics research lab. (TSX:NUMI, OTC:LKYSF) said it has completed the acquisition of Novamind Inc (CSE:NM) following the latter's receipt of a final order from the British Columbia Supreme Court. Application is in qc review meaning with ramp assistance.Numinus Wellness Inc.
0 kommentar(er)
